MESOBLAST ADR Aktie

 

This stock has exploded in the last month The post Heres what $1k invested in Mesoblast shares a month ago is worth now appeared first on The Motley Fool Australia....

Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out....

More big returns could be on the way for buyers of this high risk stock according to Bell Potter. The post Why Mesoblast shares can keep storming higher appeared first on The Motley Fool Australia....

These shares are ending the week with a bang. But why? The post Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher appeared first on The Motley Fool Australia....

ASX investors just sent the Mesoblast share price up 38%. But why? The post The Mesoblast share price just rocketed 38%! Here's why appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation....

The ASX biotech share reached a 10-week high of $1.94 today. The post Why is the Mesoblast share price up 11% in June? appeared first on The Motley Fool Australia....

The overall chronic lower back pain market is expected to boost with the expected launch of emerging therapies such as SP-102 (Scilex Holding), Rexlemestrocel-L (Mesoblast Limited), Cebranopadol (TRN-228) (Tris Pharma), and others, increased awareness, and extensive research in the......

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD)....

Good Afternoon and welcome to HotCopper Highlights for Week 20, I'm Jon…...

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older....

The ASX200 has been trading flat at around 8,280 points. Mesoblast (ASX:MSB)…...

Mesoblast (ASX:MSB) has revealed the US FDA has given its flagship drug…...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025....

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited....

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for Ryoncil® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, to 104 million US lives insured by government and commercial payers....

Big returns could be on offer from this biotech according to Bell Potter. The post Top broker says Mesoblast shares can rocket 100% appeared first on The Motley Fool Australia....

Good Afternoon and welcome to this edition of HotCopper Highlights, I'm Jonathon…...

The ASX has been down 1.5% at 7,739 points this morning. There's…...